Molecular targets of gemcitabine action: Rationale for development of novel drugs and drug combinations

Current Pharmaceutical Design

Volumn 18, Issue 19, 2012, Pages 2811-2829

  Elnaggar, Maha ^a,b   Giovannetti, Elisa ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

Cytidine deaminase; Drug combination; Emcitabine; Equilibrative transporter 1; Pharmacogenetics; Radiosensitization

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTIDINE DEAMINASE; CYTIDINE DIPHOSPHATE; CYTIDINE TRIPHOSPHATE SYNTHASE; DNA DEPENDENT PROTEIN KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERLOTINIB; ETOPOSIDE; FAS ANTIGEN; GEFITINIB; GEMCITABINE; GEMCITABINE ELAIDATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; LY2334737; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NUC 1031; PACLITAXEL; PEMETREXED; PROTEIN BAX; PROTEIN KINASE C; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; SEMAXANIB; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DNA SYNTHESIS INHIBITION; DROSOPHILA MELANOGASTER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE EXPRESSION; GENE INSERTION; HEAD AND NECK CANCER; HUMAN; IC 50; IMMUNOGENICITY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEOMICS; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84862528550     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800626175     Document Type: Article

References (232)

1. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 Suppl 5: v7-12
2. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19-33.
3. Fabi A, Mirri A, Felici A, et al. Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. J Neurooncol 2008; 87: 79-84.
4. Sigmond J, Honeywell RJ, Postma TJ, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 2009; 20: 182-7.
5. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349-57.
6. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-31.
7. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
8. Ruiz van Haperen V, Veerman G, Vermorken JB, Peters GJ. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993; 46: 762-6.
9. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol.Pharmacol 1990; 38: 567-72.
10. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of selfpotentiation. Cancer Res 1992; 52: 533-9.
11. Ciccolini J, Mercier C, Dahan L, Andre N. Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 2011; 8: 439-44.
12. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009; 10: 1657-74
13. Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res 2002; 112: 27-47.
14. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 2008; 38: 972-94.
15. Damaraju S, Zhang J, Visser F, et al. Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet. Genomics 2005; 15: 173-82.
16. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics 2006; 16: 315-20.
17. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 753-7.
18. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956-61.
19. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-35.
20. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-95.
21. Mey V, Giovannetti E, De Braud F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006; 95: 289-97.
22. Osato DH, Huang CC, Kawamoto MJ, et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 2003; 13: 297-301.
23. Leabman MK, Huang CC, DeYoung J, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003; 100: 5896-901
24. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenetics of of gemcitabine. Can genetic studies lead tailor-made therapy? Brit J Cancer 2007; 97: 145-51.
25. Kim SR, Saito Y, Maekawa K, et al. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet 2006; 21: 248-56.
26. Gray JH, Mangravite LM, Owen RP, et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004; 65: 512-9.
27. Soo RA, Wang LZ, Ng SS, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009; 63: 121-7.
28. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-302.
29. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol.Pharmacol 2003; 63: 1094-103.
30. Adema AD, Floor K, Smid K, Honeywell RJ, Peters GJ. Overexpression of MRP4 or MRP5 confers resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Mol Cancer Ther 2009; 8(12 suppl) B65; doi: 10.1158/1535-7163.TARG-09-B65 (Abstract)
31. Bergman AM, Adema AD, Balzarini J, et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 2011; 29: 456-66.
32. Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br.J.Haematol 2009; 144: 273-5.
33. Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ. Innovations and opportunities to improve conventional (deoxy) nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem 2009; 16: 4632-43.
34. Ruiz van Haperen V, Veerman G, Eriksson S, et al. Development and molecular characterization of a 2',2'-difluorodeoxycytidineresistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994; 54: 4138-43.
35. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol.Cancer Ther 2002; 1: 371-6.
36. Dumontet C, Fabianowska-Majewska K, Matincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999; 106: 78-85.
37. Al-Madhoun AS, van der Wilt CL, Loves WJ, et al. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Biochem.Pharmacol 2004; 68: 601-9.
38. Vernejoul F, Ghenassia L, Souque A, et al. Gene Therapy Based on Gemcitabine Chemosensitization Suppresses Pancreatic Tumor Growth. Molecular therapy 2006; 14: 758-67.
39. Sigmond J, Kroep JR, Loves W, Codacci-Pisanelli G, Peters GJ. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity. Cancer Lett 2004; 213: 173-9.
40. Keszler G, Spasokoukotskaja T, Sasvari-Szekely M, Eriksson S, Staub M. Deoxycytidine kinase is reversibly phosphorylated in normal human lymphocytes. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1147-51.
41. Smal C, Vertommen D, Bertrand L, et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 2006; 281: 4887-93.
42. Peters GJ, Hodzic J, Ortega B, et al. Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase. Nucleosides Nucleotides Nucleic Acids 2010; 29: 408-13.
43. Sebastiani V, Ricci F, Rubio-Viqueira B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 2006; 12: 2492-7.
44. Marechal R, Mackey JR, Lai R, et al. Deoxycytidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010; 116: 5200-6.
45. Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323: 935-45.
46. Kocabas NA, Aksoy P, Pelleymounter LL, et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab. Dispos 2008; 36: 1951-9.
47. Kim SR, Saito Y, Maekawa K, et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK) Drug Metab. Pharmacokinet 2008; 23: 379-84.
48. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 2006; 62; 681-4.
49. Shi JY, Shi ZZ, Zhang SJ, et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14: 759-68.
50. Wang L, Munch-Petersen B, Herrstrom SA, et al. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett 1999; 443: 170-4.
51. Bergman AM, Munch-Petersen B, Jensen PB, et al. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin-and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem.Pharmacol 2001; 61: 1401-8.
52. Nielsen SE, Munch-Petersen B, Mejer J. Increased ratio between deoxycytidine kinase and thymidine kinase 2 in CLL lymphocytes compared to normal lymphocytes. Leuk Res 1995; 19: 443-7.
53. Hunsucker SA, Mitchell BS, Spychala J. The 5 ′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005; 107: 1-30
54. Hunsucker SA, Spychala J, Mitchell BS. Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. J Biol Chem 2001; 276: 10498-504.
55. Seve P, Mackey JR, Isaac S, et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 2005; 49: 363-70.
56. Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 1388-94
57. Mitra A K, Crew K R, Pounds S, et al. Genetic Variants in Cytosolic 5_-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. JPET 2011; 339: 9-23.
58. Aksoy P, Zhu MJ, Kalari KR, et al. Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet. Genomics 2009; 19; 567-76.
59. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem.Pharmacol 1993; 45: 1857-61.
60. Honeywell R, Giovannetti E, Peters GJ. Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. Nucleosides, Nucleotides and Nucleic acids 2011; 30: 1203-13.
61. Bergman AM, Pinedo HM, Jongsma AP, et al. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem.Pharmacol 1999; 57: 397-406.
62. Ruiz van Haperen VW, Veerman G, Braakhuis BJ, et al. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 1993; 29A: 2132-7
63. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp.Hematol 1996; 24: 1340-6.
64. Eliopoulos N, Cournoyer D, Momparler RL. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother. Pharmacol 1998; 42: 373-8.
65. Ogawa M, Hori H, Ohta T, Onozato K, Miyahara M, Komada Y. Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin.Cancer Res 2005; 11: 3485-93.
66. Yoshida T, Endo Y, Obata T, Kosugi Y, Sakamoto K, Sasaki T. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo. Drug Metab Dispos 2010; 38: 1814-9.
67. Eda H, Ura M, Ouchi K, Tanaka Y, Miwa M, Ishitsuka H. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res 1998; 58: 1165-9.
68. Yonemori K, Ueno H, Okusaka T, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin.Cancer Res 2005; 11: 2620-4.
69. Mercier C, Raynal C, Dahan L, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet.Genomics 2007; 17: 841-4.
70. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br.J.Haematol 1998; 103: 1096-103.
71. Bengala C, Guarneri V, Giovannetti E, et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br.J.Cancer 2005; 93: 35-40.
72. Ciccolini J, Dahan L, Andre N, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J.Clin.Oncol 2010; 28: 160-5.
73. Raynal C, Ciccolini J, Mercier C, et al. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. Ther.Drug Monit 2010; 32: 53-60.
74. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics.J 2004; 4: 307-14.
75. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J.Clin.Oncol 2007; 25: 32-42.
76. Yue L, Saikawa Y, Ota K, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003; 13: 29-38.
77. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin.Cancer Res 2006; 12: 1794-803.
78. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin.Cancer Res 2010; 16: 320-9.
79. Giovannetti E, Laan AC, Vasile E, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008; 27: 720-5.
80. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin.Cancer Res 2008; 14: 1797-803.
81. Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann.Oncol 2012; 23: 670-7.
82. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 2001; 61: 8723-9.
83. Ruiz van Haperen VW, Veerman G, Boven E, et al. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994; 48: 1327-39.
84. van Moorsel CJ, Bergman AM, Veerman G, et al. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim.Biophys.Acta 2000; 1474: 5-12.
85. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin.Oncol 1996; 23: 3-15.
86. Bergman AM, Eijk PP, Ruiz van Haperen V, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65: 9510-6.
87. Reichard P. Ribonucleotide reductases: substrate specificity by allostery. Biochem. Biophys. Res. Commun 2010; 396: 19-23.
88. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ. Overview of ribonucleotide reductase inhibitors: an appealing target in antitumour therapy. Curr.Med.Chem 2005; vol 12: 1283-94.
89. van Der Donk WA, Yu G, Perez L, et al. Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5'-diphosphate. Biochemistry 1998; 37; 6419-26.
90. Stubbe J. Ribonucleotide reductases: amazing and confusing. J.Biol.Chem 1990; 265; 5329-32.
91. Cerqueira NM, Fernandes PA, Ramos MJ. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2007; 2: 11-29.
92. Wang J, Lohman GJ, Stubbe J. Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate. Biochemistry 2009; 48; 11612-21.
93. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404: 42-9.
94. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall-cell lung cancer. J.Clin.Oncol 2006; 24: 4731-7.
95. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J.Clin.Oncol 2004; 22: 1878-85.
96. Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-92.
97. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64: 3761-6.
98. van de Wiel MA, Costa JL, Smid K, et al. Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations. Cancer Res 2005; 65: 10208-13.
99. Kazuno H, Sakamoto K, Fujioka A, Fukushima M, Matsuda A, Sasaki T. Possible antitumor activity of 1-(3-C-ethynyl-beta-dribopentofuranosyl) cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line. Cancer Sci 2005; 96: 295-302.
100. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96: 457-63.
101. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007; 120: 1355-63.
102. Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 2005; 4: 1268-76.
103. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin.Cancer Res 2004; 10: 1318-25.
104. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int 2010; 106; 1805-11.
105. Kwon WS, Rha SY, Choi YH, et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics 2006; 16: 429-38.
106. Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int J Oncol 2003; 22: 201-7
107. Peters GJ, Van Moorsel CJ, Lakerveld B, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 2006; 28: 237-44
108. Jordheim L P, Sève P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer, Lancet oncology 2011; 12: 693-702.
109. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin. Oncol 1995; 22: 19-25.
110. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063-74.
111. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008; 27: 6522-37.
112. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur.J.Cancer 1999; 35: 796-807.
113. Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabinemediated cytotoxicity and radiosensitization. Cancer Chemother. Pharmacol 2000; 45: 369-74.
114. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97: 439-45.
115. Cascallo M, Calbo J, Gelpi JL, Mazo A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000; 7: 545-56.
116. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-62.
117. Xu ZW, Friess H, Solioz M, et al. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001; 94: 268-74
118. Xu ZW, Friess H, Buchler MW, Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother.Pharmacol 2002; 49: 504-10.
119. Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol.Cancer Ther 2002; 1: 1221-7.
120. Pace E, Melis M, Siena L, et al. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 2000; 46: 467-76.
121. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-60.
122. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000; 60: 7133-41.
123. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-51.
124. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factorkappaB-regulated gene products. Cancer Res 2007; 67: 3853-61.
125. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064-72.
126. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65: 6934-42.
127. Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res 2009; 29: 3173-8.
128. Liu A, Chen H, Tong H, et al. Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. Mol.Med.Report 2011; 4: 221-7.
129. Shan T, Ma Q, Zhang D, et al. beta2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur.J.Pharmacol 2011; 665: 1-7.
130. Habiro A, Tanno S, Koizumi K, et al. Involvement of p38 mitogenactivated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 2004; 316: 71-7.
131. Gorospe M. HuR in the mammalian genotoxic response: posttranscriptional multitasking. Cell Cycle 2003; 2: 412-4.
132. Costantino CL, Witkiewicz AK, Kuwano Y, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. Cancer Res 2009; 69: 4567-72.
133. Hostetter C, Licata LA, Witkiewicz A, et al. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol.Ther 2008: 7; 1496-506
134. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65: 3168-81.
135. Lopez de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2: 11-3.
136. Richards NG, Rittenhouse DW, Freydin B, et al. HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. Annals of Surgery 2010; 252: 499-506.
137. Tempero M, Plunkett W, Ruiz van Haperen V V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-8.
138. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002; 95: 941-5.
139. Hochster HS. Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. Int J Radiat Oncol Biol Phys 2003; 56: 24-30.
140. van Riel JM, Peters GJ, Mammatas LH, et al. A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur.J.Cancer 2009; 45: 2519-27.
141. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 2008; 9: 251-66.
142. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005; 10: 34-51.
143. Gregoire V, Hittelman WN, Rosier JF, Milas L. Chemoradiotherapy: radiosensitizing nucleoside analogues (review). Oncol Rep 1999; 6: 949-57.
144. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996; 14: 257-63.
145. Pauwels B, Korst AE, de Pooter CM, et al. The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. Eur.J.Cancer 2003; 39: 838-46.
146. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int.J.Radiat.Oncol.Biol.Phys 1996; 34: 867-72.
147. Genç M, Castro Kreder N, Barten-van Rijbroek A, Stalpers LJ, Haveman J. Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids. J Cancer Res Clin Oncol 2004; 130: 45-51.
148. Van Bree C, Castro Kreder N, Loves WJP, Franken NAP, Peters GJ, Haveman J. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiation Oncol Biol Phys 2002; 54; 237-44.
149. Pauwels B, Korst AE, Lambrechts HA, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 2006; 58: 219-28.
150. Peters GJ, Clavel M, Noordhuis P, et al. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. J. Chemother 2007; 19; 212-221.
151. De Lange SM, Van der Born K, Kroep JR, et al. No evidence of gemcitabine accumulation during weekly administration. Eur. J. Clin. Pharmacol 2005; 61; 843-849.
152. De Lange SM, Van Groeningen CJ, Meijer OWM, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur. J. Cancer 2002; 38; 1212-1217.
153. Metro G, Fabi A, Mirri MA, et al. Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol 2010; 65: 391-7.
154. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitiza tion of human colon carcinoma cells. Cancer Res 1994; 54: 3218-23.
155. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Cancer Res 2000; 60: 6080-8.
156. Van Putten JWG, Groen HJM, Smid K, Peters GJ, Kampinga HM. Endjoining deficiency and radiosensitation induced by gemcitabine. Cancer Res. 2011; 61; 1585-1591.
157. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int.J.Radiat.Oncol.Biol.Phys 1998; 41: 875-82.
158. Robinson BW, Shewach DS. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin.Cancer Res 2001; 7: 2581-9.
159. Pauwels B, Korst AE, Pattyn GG, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int.J.Radiat.Oncol.Biol.Phys 2003; 57: 1075-83.
160. Wachters FM, Van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, Kampinga HH. Selective targeting of homologous DNA recombination repair by gemcitabine. Int.J.Radiat.Oncol.Biol.Phys 2003; 57: 553-62.
161. Weiss C, Grabenbauer GG, Sauer R, Distel L. Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine. Strahlenther.Onkol 2003; 179: 93-8.
162. Gregoire V, Rosier JF, De Bast M et al. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiother Oncol 2002; 63: 329-338.
163. Pauwels B, Korst AEC, Pattyn GGO, et al. The relation between deoxycytidine kinase activity and the radiosensitizing effect of gemcitabine in eight different human tumor cell lines. BMC Cancer 2006; 6; 142 (doi: 10.1186/1471-2407-6-142).
164. Haveman J, Sigmond J, Van Bree C, Franken NA, Koedooder C, Peters GJ. Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation. Oncol. Rep 2006. 16; 901-905.
165. Sigmond J, Haveman J, Castro Kreder N, et al. Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma-irradiation. Nucleosides Nucleotides Nucleic Acids 2006; 25; 1177-1180
166. Berlin J, Catalano P, Thomas JP et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. J. Clin. Oncol 2002, 20,3270-3275.
167. Colucci G, Giuliani F, Gebbia V et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and metastatic pancreatic carcinoma. Cancer 2002, 94, 902-910
168. Bramhall SR, Schulz J, Nemunaitis J et al.: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002, 87,161-167.
169. Van Cutsem E, van de Velde H, Karasek P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol 2004; 22; 1430-1438
170. Rocha Lima CM, Green MR, Rotche R et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol 2004, 22; 3776-3783
171. Richards DA, Kindler HL, Oettle H, et al: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer (abstract 4007). Proc Am Soc Clin Oncol 23: LBA 2004.
172. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J.Clin.Oncol 2007; 25: 1960-6.
173. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J.Clin.Oncol 2010; 28: 3617-22.
174. Fountzilas G, Bobos M, Kalogera-Fountzila A, et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 2008; 26: 784-93.
175. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabinecisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999, 17, 12-18
176. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000, 18, 122-130
177. Mok TSK, Zee B, Chan A T.C, Yeo W, Wei Tse Yang W T, et al: A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma, Cancer 2000, 89, 543-550.
178. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
179. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
180. Smit EF, Van Meerbeeck J P.A.M., Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, et al Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. Journal of Clinical Oncology 2003: 21, 3909-3917
181. Treat J. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 2003; 21: 624.
182. Monnerat C, Le CT, Kelly K et al. Phase II study of pemetrexedgemcitabine combination in patients with advanced-stage nonsmall cell lung cancer. Clin Cancer Res 2004; 10: 5439-5446.
183. McCleod M, Treat J, Christiansen N et al. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC): a phase II clinical trial. Proc Am Soc ClinOncol 2005; 23, 650s (abstr 7121)
184. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005; 41: 81-92.
185. Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/ carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97: 283-289.
186. Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49: 233-240.
187. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-smallcell lung cancer: a phase II study. J.Clin.Oncol 1994; 12: 1535-40.
188. Bergman AM, Ruiz van Haperen, V, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin.Cancer Res 1996; 2: 521-30.
189. van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and nonsmallcell lung cancer cell lines. Br.J.Cancer 1999; 80: 981-90.
190. Braakhuis BJ, Ruiz van Haperen V, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur.J.Cancer 1995; 31A: 2335-40.
191. van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur.J.Cancer 1999; 35: 808-14.
192. van Moorsel CJ, Pinedo HM, Smid K, et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000; 36: 2420-2429.
193. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol.Ther 2000; 87: 227-53.
194. Edelman MJ, Quam H, Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother.Pharmacol 2001; 48: 141-4.
195. Chow KC, Macdonald TL, Ross WE. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol.Pharmacol 1988; 34: 467-73.
196. van Moorsel CJ, Pinedo HM, Veerman G, et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem.Pharmacol 1999; 57: 407-15.
197. Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br.J.Cancer 2000; 83: 1069-76.
198. Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel; pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J. Clin. Oncol 1999; 17; 2190-2197.
199. Giovannetti E, Danesi R, Mey V, et al. In vitro studies on gemcitabine combinations with other antiblastics. Ann.Oncol 2006; 17 Suppl 5: v17-v19.
200. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin.Cancer Res 2004; 10: 2936-43.
201. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol.Pharmacol 2005; 68: 110-8.
202. De Pas TM, Toffalorio F, Giovannetti E, et al. Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Nonsmall Cell Lung Cancer: A Pharmacogenetic Approach. J.Thorac.Oncol 2011; 6: 768-73.
203. Safran H, Miner T, Resnick M, et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am.J.Clin.Oncol 2008; 31: 140-4.
204. van Moorsel CJ, Kroep JR, Pinedo HM, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann.Oncol 1999; 10: 441-8.
205. Kroep JR, Peters GJ, Van Moorsel CJA, et al. Gemcitabine-cisplatin; a schedule finding Phase I study. Ann. Oncol 1999; 10; 1503-1510.
206. Kuenen BC, Rosen L, Smit EF, et al. Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. J. Clin. Oncol 2002; 20; 1657-1667.
207. Giaccone G, González-Larriba JL, Van Oosterom AT, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann. Oncol 2004; 15; 831-838.
208. Kroep JR, Smit EF, Giaccone G, et al. Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol 2006; 58; 509-516.
209. Sigmond J, Kamphuis J.A, Laan A.C, Hoebe E.K, Bergman A.M, Peters G.J, The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem.Pharmacol 2007; 73; 1548-1557
210. Traynor A.M, Lee J.W, Bayer G.K, Tate J.M, Thomas S.P, Mazurczak M, Graham D.L, Kolesar J.M, Schiller J.H; A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs.2010; 28; 91-97
211. Peters GJ, Adema AD, Bijnsdorp IV, Sandvold ML. Lipophilic prodrugs and formulations of conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Nucleosides, Nucleotides and Nucleic Acids 2011; 30: 1168-80.
212. Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Fodstad Ø, Breistøl K, Peters GJ. Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides, Nucleotides & Nucleic Acids 2004, 23; 1329-1333.
213. Sandvold ML, Galmarini CM, Myhren F, Peters GJ. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues. Nucleosides, Nucleotides and Nucleic Acids 2010, 29; 386-393.
214. Adema AD, Losekoot N, Smid K, Verheul HM, Myhren F, Sandvold ML, Peters GJ. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest. New Drugs 2011, in press.
215. Ikdahl T, Davidenko I, Bassi C, Tomasetto E, Smith L, McLachlan S, Jones S, Raponi M, Isaacson J, Voong C, Rolfe L, Allen AR, Poplin E; A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy. J Clin Oncol 29: 2011 (suppl; abstr TPS144)
216. Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 2009; 52: 6958-61.
217. Pratt SE, Shepard RL, Durland-Busbice S, Heinz-Taheny K, Dantz AH. Carboxylesterase 2 hydrolyzes a gemcitabine prodrug (LY2334737) and provides a patient tailoring biomarker. Proc. Amer Assoc Cancer Res 2011; 52; abstract 2981
218. Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6071-82.
219. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 2008; 14: 3477-86.
220. Alexander, R.L, Greene, B.T, Torti, S.V, Kucera, G.L. A novel phospholipid gemcitabine conjugate is able to bypass three drugresistance mechanisms. Cancer Chemother. Pharmacol 2005, 56, 15-21.
221. Wu, W, Sigmond, J, Peters, G.J, Borch, R.F. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J. Med. Chem 2007, 50, 3743-6.
222. McGuigan C, Habib NA, Wasan HS, Gabra H, Jiao LR, Slusarczyk M, Chabot JA, Saif MW; A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine. J Clin Oncol 29: 2011 (suppl; abstr e13540)
223. Patra, C.R, Bhattacharya, R, Wang, E, Katarya, A, Lau, J.S, Dutta, S, Muders, M, Wang, S, Buhrow, S.A, Safgren, S.L, Yaszemski, M.J, Reid, J.M, Ames, M.M, Mukherjee, P, Mukhopadhyay, D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008, 68, 1970-8.
224. Couvreur, P, Reddy, L.H, Mangenot, S, Poupaert, J.H, Desmaele, D, Lepetre-Mouelhi, S, Pili, B, Bourgaux, C, Amenitsch, H, Ollivon, M. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 2008, 4, 247-53.
225. Reddy, L.H, Khoury, H, Paci, A, Deroussent, A.; Ferreira, H.; Dubernet, C.; Decleves, X, Besnard, M, Chacun, H, Lepetre-Mouelhi, S, Desmaele, D, Rousseau, B, Laugier, C, Cintrat, J.C, Vassal, G, Couvreur, P. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos 2008, 36, 1570-7.
226. Pasut, G, Canal, F, Dalla, V.L, Arpicco, S, Veronese, F.M, Schiavon, O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control Release 2008, 127, 239-48.
227. Celano, M, Calvagno, M.G, Bulotta, S, Paolino, D, Arturi, F, Rotiroti, D, Filetti, S, Fresta, M, Russo, D. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC. Cancer 2004, 4, 63.
228. Celia, C, Malara, N, Terracciano, R, Cosco, D, Paolino, D, Fresta, M, Savino, R. Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine 2008, 4, 155-66.
229. Paolino, D, Cosco, D, Licciardi, M, Giammona, G, Fresta, M, Cavallaro, G. Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs. Biomacromolecules 2008, 9, 1117-30
230. Zhu Z, Ma S, Zhao L, Sun Z, He A, Xu H, Zheng X. Adenovirusmediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile. Int J Oncol 2011; 38: 745-53.
231. Giovannetti E, Mey V, Nannizzi S, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol.Cancer Ther 2006; 5: 1387-95
232. Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv.Drug Deliv.Rev 2009; 61: 408-17.